Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01387555 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2 study, sponsored by Jennerex Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT01387555: Completed Phase 2 study, sponsored by Jennerex Biotherapeutics.
NCT01387555 is a Phase 2 study that has completed, run by Jennerex Biotherapeutics. The registered enrollment target is 129 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01387555, a Phase 2 study, has completed, sponsored by Jennerex Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
This study is to determine whether JX-594 (Pexa-Vec) plus best supportive care is more effective in improving survival than best supportive care in patients with advanced Hepatocellular Carcinoma (HCC) who have failed sorafenib.
Primary Outcome
Determine overall survival for patients receiving JX-594 plus best supportive care (Arm A) compared with those patients receiving best supportive care (Arm B) in patients with advanced hepatocellular carcinoma (HCC) who have failed sorafenib treatment.
Interventions
- OTHER Best Supportive Care
- BIOLOGICAL JX-594 recombinant vaccina GM-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2011-10-08 |
| Est. Completion | 2013-10-01 |
| Phase | Phase 2 |
What the finished NCT01387555 record still lists
NCT01387555 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Best Supportive Care is the first listed.
NCT01387555 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01387555 about?
NCT01387555 is a clinical study titled "A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib". This study is to determine whether JX-594 (Pexa-Vec) plus best supportive care is more effective in improving survival than best supportive care in patients with advanced Hepatocellular Carcinoma (HCC) who have failed sorafenib.
What is the current status of trial NCT01387555?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2011-10-08. Estimated completion is 2013-10-01.
What interventions are being tested in trial NCT01387555?
The interventions under investigation include: Best Supportive Care (OTHER), JX-594 recombinant vaccina GM-CSF (BIOLOGICAL).
Who is sponsoring clinical trial NCT01387555?
This trial is sponsored by Jennerex Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01387555's enrollment target sits among peer trials
129 553rd of 2000 higher than 1,448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI